|Awarded On||May 20, 2015|
|Title||Elevated D-2-hydroxyglutarate precedes and promotes tumor progression in inflammatory bowel diseases|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Baylor Research Institute|
|Principal Investigator/Program Director||Arianne Theiss|
Inflammatory bowel diseases (IBD), the most common forms being Crohn’s disease and ulcerative colitis (UC), are characterized by chronic inflammation of the gastrointestinal tract. IBD patients are at an increased risk compared to the general public of developing colorectal cancer. Although the association between IBD and progression to colitis-associated cancer is well-established, the mechanisms driving progression from colitis to cancer remain poorly understood. Moreover, biomarkers and functional therapeutic targets to detect, predict, and prevent colitis-associated cancer are currently lacking. Accumulation of the metabolite D-2-hydroxyglutarate (D-2-HG), which is normally produced at l...